High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma

被引:34
作者
Smith, Ross [1 ]
Xue, AiQun
Gill, Anthony
Scarlett, Christopher
Saxby, Alexander
Clarkson, Adele
Hugh, Thomas
机构
[1] Univ Sydney, Royal N Shore Hosp, Dept Surg, St Leonards, NSW 2065, Australia
[2] Univ Sydney, Royal N Shore Hosp, Dept Pathol Anat, St Leonards, NSW, Australia
关键词
D O I
10.1007/s00268-006-0289-9
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Recent findings suggest that the urokinase-type plasminogen activator (uPA), its receptor (uPAR), plasminogen activator inhibitor-1 (PAI-1), and -2 (PAI-2) play key roles in cancer invasion. Summary Background Data: The prognostic value of components of this system is well established in breast cancer. However, little is known of its involvement in pancreatic cancer (PC). Methods: Quantitative real-time polymerase chain reaction (Q-RT-PCR) was used on tissue-banked specimens and immunohistochemistry (IHC) on paraffin specimens was used to measure expression of uPA, uPAR, PAI-1, and PAI-2 proteins in 46 PC and 12 cystadenoma specimens. Results were related to survival using Cox's proportional hazards testing. Results: Increased expression of uPA, uPAR, and PAI-1 in PC tissue were independently associated with a higher Union Internationale Contre le Cancer [International Union Against Cancer (UICC)] tumor stage (P < 0.001) and were intercorrelated (P < 0.001). Overexpression of uPAR indicated reduced survival (P = 0.03). Conversely, PAI-2 messenger ribonucleic acid (mRNA) overexpression, which occurred in 21 of 46 tumors, negatively correlated with tumor size (P = 0.008) and survival (P < 0.007) but not with uPA, uPAR, or tumor stage. There was good agreement between PAI-2 mRNA value and IHC score (P < 0.001). Using Cox's stepwise analysis, PAI-2 mRNA value (HR = 0.24; P = 0.001) and UICC tumor stage (HR = 2.014; P = 0.001) independently predicted survival. An IHC score for PAI-2 of 3+ or 4+ also independently predicted improved survival (HR = 2.72; P = 0.025). Conclusions: The uPA/uPAR/PAI-1 system is activated in advanced pancreatic cancer and may account for the tumor's aggressive behavior, whereas PAI-2 expression appears to be independent of uPA/uPAR/PAI-1 and is associated with improved prognosis. Because of its intercorrelation with mRNA expression, PAI-2 IHC may be used as an indicator of survival.
引用
收藏
页码:493 / 503
页数:11
相关论文
共 45 条
  • [1] A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types
    Abi-Habib, Ralph J.
    Singh, Ravibhushan
    Liu, Shihui
    Bugge, Thomas H.
    Leppla, Stephen H.
    Frankel, Arthur E.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (10) : 2556 - 2562
  • [2] Targeted alpha therapy for cancer
    Allen, BJ
    Raja, C
    Rizvi, S
    Li, Y
    Tsui, W
    Zhang, D
    Song, E
    Qu, CF
    Kearsley, J
    Graham, P
    Thompson, J
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2004, 49 (16) : 3703 - 3712
  • [3] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - PROENZYME, RECEPTOR, AND INHIBITORS
    BLASI, F
    VASSALLI, JD
    DANO, K
    [J]. JOURNAL OF CELL BIOLOGY, 1987, 104 (04) : 801 - 804
  • [4] High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer
    Borgfeldt, C
    Bendahl, PO
    Gustavsson, B
    Långström, E
    Fernö, W
    Willén, R
    Grenman, S
    Casslén, B
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (04) : 658 - 665
  • [5] Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma
    Cantero, D
    Friess, H
    Deflorin, J
    Zimmermann, A
    Brundler, MA
    Riesle, E
    Korc, M
    Buchler, MW
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (03) : 388 - 395
  • [6] CHAMBERS SK, 1995, CANCER, V75, P1627, DOI 10.1002/1097-0142(19950401)75:7<1627::AID-CNCR2820750712>3.0.CO
  • [7] 2-V
  • [8] Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer
    Cufer, T
    Borstnar, S
    Vrhovec, I
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2003, 18 (02) : 106 - 115
  • [9] The urokinase plasminogen activator system: Role in malignancy
    Duffy, MJ
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (01) : 39 - 49
  • [10] Invasion and metastasis in pancreatic cancer
    Ellenrieder, V
    Adler, G
    Gress, TM
    [J]. ANNALS OF ONCOLOGY, 1999, 10 : 46 - 50